{
    "accountDetails": {
        "accountHasCodexViolations": false,
        "activeDateRanges": [
            {
                "fromDate": "2023-11-08T10:05:07.000+01:00"
            }
        ],
        "firstPublicationDate": "2023-11-08T10:05:07.000+01:00",
        "lastUpdateDate": "2024-06-25T14:05:03.000+02:00",
        "registerEntryVersions": [
            {
                "legislation": "GL2024",
                "registerEntryId": 36342,
                "validFromDate": "2024-06-25T14:05:03.000+02:00",
                "version": 2,
                "versionActiveLobbyist": true
            },
            {
                "legislation": "GL2022",
                "registerEntryId": 20126,
                "validFromDate": "2023-11-08T10:05:07.000+01:00",
                "validUntilDate": "2024-06-25T14:05:03.000+02:00",
                "version": 1,
                "versionActiveLobbyist": true
            }
        ]
    },
    "activeLobbyist": true,
    "activitiesAndInterests": {
        "activity": {
            "code": "ACT_ORGANIZATION_V2",
            "de": "Sonstiges Unternehmen",
            "en": "Other company"
        },
        "activityDescription": "Daiichi Sankyo ist ein forschendes, globales Pharmaunternehmen mit Sitz in Japan, das in mehr als 20 L\u00e4ndern weltweit vertreten ist. Europ\u00e4ischer Hauptsitz ist in M\u00fcnchen; haupts\u00e4chlich t\u00e4tig in den Bereichen Kardiologie & Onkologie.\r\n\r\nDaiichi Sankyo ist an EU-Initiativen und politischen Entwicklungen interessiert, die sich auf unsere Schwerpunkte in Forschung, Entwicklung, Herstellung und Kommerzialisierung von innovativen Arzneimitteln beziehen. Dazu geh\u00f6ren Themen wie Gesundheitspolitik, globale Gesundheit, Datenschutz, relevante Arzneimittelgesetze, klinische Studien, Medizinprodukte, Handel, Schutz von geistigem Eigentum, sowie Umwelt und Nachhaltigkeit.\r\n\r\nDurch offenen und zukunftsgerichteten Dialog mit Stakeholdern soll ein Beitrag geleistet werden, gemeinsam L\u00f6sungsans\u00e4tze f\u00fcr eine bestm\u00f6gliche Versorgung von Patient*innen mit (innovativen) Arzneimitteln sicherzustellen. ",
        "fieldsOfInterest": [
            {
                "code": "FOI_HEALTH_PROMOTION",
                "de": "Gesundheitsf\u00f6rderung",
                "en": "Health promotion"
            },
            {
                "code": "FOI_ECONOMY_INDUSTRIAL",
                "de": "Industriepolitik",
                "en": "Industrial policy"
            },
            {
                "code": "FOI_WORK",
                "de": "Arbeit und Besch\u00e4ftigung",
                "en": "Work and employment"
            },
            {
                "code": "FOI_FOREIGN_AFFAIRS",
                "de": "Au\u00dfenpolitik und internationale Beziehungen",
                "en": "Foreign policy and international relations"
            },
            {
                "code": "FOI_FOREIGN_TRADE",
                "de": "Au\u00dfenwirtschaft",
                "en": "Foreign trade"
            },
            {
                "code": "FOI_HEALTH_SUPPLY",
                "de": "Gesundheitsversorgung",
                "en": "Health supply"
            },
            {
                "code": "FOI_FA_INTERNATIONAL",
                "de": "Internationale Beziehungen",
                "en": "International relations"
            },
            {
                "code": "FOI_ECONOMY",
                "de": "Wirtschaft",
                "en": "Economy"
            },
            {
                "code": "FOI_HEALTH_MEDICINE",
                "de": "Arzneimittel",
                "en": "Medicine"
            },
            {
                "code": "FOI_HEALTH",
                "de": "Gesundheit",
                "en": "Health"
            },
            {
                "code": "FOI_EU_DOMESTIC_MARKET",
                "de": "EU-Binnenmarkt",
                "en": "EU internal market"
            },
            {
                "code": "FOI_SCIENCE_RESEARCH_TECHNOLOGY",
                "de": "Wissenschaft, Forschung und Technologie",
                "en": "Science, research and technology"
            },
            {
                "code": "FOI_EUROPEAN_UNION",
                "de": "Europapolitik und Europ\u00e4ische Union",
                "en": "European politics and the EU"
            },
            {
                "code": "FOI_EU_LAWS",
                "de": "EU-Gesetzgebung",
                "en": "EU legislation"
            },
            {
                "code": "FOI_WORK_POLICY",
                "de": "Arbeitsmarkt",
                "en": "Job market"
            }
        ],
        "typesOfExercisingLobbyWork": [
            {
                "code": "SELF_OPERATED_OWN_INTEREST",
                "de": "Die Interessenvertretung wird in eigenem Interesse selbst wahrgenommen",
                "en": "Interest representation is self-performed in its own interest"
            },
            {
                "code": "CONTRACTS_OPERATED_BY_THIRD_PARTY",
                "de": "Die Interessenvertretung wird in eigenem Interesse durch die Beauftragung Dritter wahrgenommen",
                "en": "Contracts are awarded to third parties to represent own interests of the company"
            }
        ]
    },
    "annualReports": {
        "annualReportPdfUrl": "https://www.lobbyregister.bundestag.de/media/fa/71/311100/Jahresabschluss-Daiichi-Sankyo-Europe-GmbH_FY22.pdf",
        "annualReportPreviousLastFiscalYearExists": true,
        "relatedFiscalYearEnd": "2023-03-31",
        "relatedFiscalYearStart": "2022-04-01"
    },
    "codeOfConduct": {
        "ownCodeOfConduct": false
    },
    "contracts": {
        "contracts": [],
        "contractsPresent": false
    },
    "donators": {
        "relatedFiscalYearEnd": "2024-03-31",
        "relatedFiscalYearFinished": true,
        "relatedFiscalYearStart": "2023-04-01",
        "totalDonationsEuro": {
            "from": 0,
            "to": 0
        }
    },
    "employeesInvolvedInLobbying": {
        "employeeFTE": 0.25,
        "relatedFiscalYearEnd": "2024-03-31",
        "relatedFiscalYearFinished": true,
        "relatedFiscalYearStart": "2023-04-01"
    },
    "financialExpenses": {
        "financialExpensesEuro": {
            "from": 640001,
            "to": 650000
        },
        "relatedFiscalYearEnd": "2024-03-31",
        "relatedFiscalYearFinished": true,
        "relatedFiscalYearStart": "2023-04-01"
    },
    "legislation": "GL2024",
    "lobbyistIdentity": {
        "address": {
            "city": "M\u00fcnchen",
            "country": {
                "code": "DE",
                "de": "Deutschland",
                "en": "Germany"
            },
            "street": "Zielstattstra\u00dfe",
            "streetNumber": "48",
            "type": "NATIONAL",
            "zipCode": "81379"
        },
        "capitalCityRepresentation": {
            "city": "Berlin",
            "email": "martin.fensch@daiichi-sankyo.eu",
            "phoneNumber": "+498978080",
            "street": "Franz\u00f6sische Stra\u00dfe ",
            "streetNumber": "47",
            "type": "NATIONAL",
            "zipCode": "10117"
        },
        "capitalCityRepresentationPresent": true,
        "contactDetails": {
            "emails": [
                {
                    "email": "martin.fensch@daiichi-sankyo.eu"
                },
                {
                    "email": "beate.sauer@daiichi-sankyo.eu"
                },
                {
                    "email": "laila.osman@daiichi-sankyo.eu"
                }
            ],
            "phoneNumber": "+498978080",
            "websites": [
                {
                    "website": "https://www.daiichi-sankyo.eu/"
                }
            ]
        },
        "entrustedPersons": [
            {
                "academicDegreeBefore": "Dr.",
                "firstName": "Martin",
                "lastName": "Fensch",
                "recentGovernmentFunctionPresent": false
            },
            {
                "firstName": "Matthias",
                "lastName": "K\u00fchn",
                "recentGovernmentFunctionPresent": false
            }
        ],
        "entrustedPersonsPresent": true,
        "identity": "ORGANIZATION",
        "legalForm": {
            "code": "LF_GMBH",
            "de": "Gesellschaft mit beschr\u00e4nkter Haftung (GmbH)",
            "en": "Limited liability company (GmbH)"
        },
        "legalFormType": {
            "code": "JURISTIC_PERSON",
            "de": "Juristische Person",
            "en": "Legal person"
        },
        "legalRepresentatives": [
            {
                "entrustedPerson": false,
                "firstName": "Masahiro",
                "function": "Gesch\u00e4ftsf\u00fchrer",
                "lastName": "Kato",
                "recentGovernmentFunctionPresent": false
            }
        ],
        "membersPresent": false,
        "memberships": [
            {
                "membership": "European Federation of Pharmaceutical Industries and Associations (EFPIA)"
            },
            {
                "membership": "European Policy Centre (EPC)"
            },
            {
                "membership": "IHK (International Chamber of Commerce Munich/Upper Bavaria)"
            },
            {
                "membership": "VBCI (Association of chemical industry in Bavaria)"
            },
            {
                "membership": "DGRA (German Society for Regulatory Affairs)"
            },
            {
                "membership": "MEGRA e.V. (Middle European Organisation for Regulatory Affairs)"
            },
            {
                "membership": "EPHMRA (Market Research + Analytics)"
            },
            {
                "membership": "Lipidinitiative Brandenburg e.V."
            },
            {
                "membership": "Verein Freiwillige Selbstkontrolle f\u00fcr die Arzneimittelindustrie e.V. (FSA)"
            },
            {
                "membership": "DGFP (Deutsche Gesellschaft f\u00fcr Personalf\u00fchrung e. V.)"
            },
            {
                "membership": "VEA (Energy consulting for energy-intensive companies)"
            },
            {
                "membership": "Bundesverband Fuhrparkmanagement e.V."
            },
            {
                "membership": "VDR (German Business Travel Association)"
            },
            {
                "membership": "Japanisches Institut in M\u00fcnchen e.V."
            },
            {
                "membership": "APV (prof. society for pharm. technology + industrial pharmacy)"
            },
            {
                "membership": "DSAG e.V. (German-speaking SAP user group="
            },
            {
                "membership": "mbuf (Microsoft Business User Forum)"
            },
            {
                "membership": "PLCD (Pharma Lizenz Club Deutschland)"
            },
            {
                "membership": "Pharmainitiative Bayern"
            },
            {
                "membership": "D-A-CH Ges. f\u00fcr Pr\u00e4vention von Herz-Kreislauf-Erkrankungen e.V."
            },
            {
                "membership": "DGA (Deutsche Gesellschaft f\u00fcr Angiologie)"
            },
            {
                "membership": "AGO e.V. "
            },
            {
                "membership": "PLCD (Pharma Lizenz Club Deutschland) e. V."
            },
            {
                "membership": "VBU (Verband der Betriebsbeauftragten) e.V."
            }
        ],
        "membershipsPresent": true,
        "name": "Daiichi Sankyo Europe GmbH"
    },
    "mainFundingSources": {
        "mainFundingSources": [
            {
                "code": "MFS_ECONOMIC_ACTIVITY",
                "de": "Wirtschaftliche T\u00e4tigkeit",
                "en": "Economic activity"
            }
        ],
        "relatedFiscalYearEnd": "2024-03-31",
        "relatedFiscalYearFinished": true,
        "relatedFiscalYearStart": "2023-04-01"
    },
    "membershipFees": {
        "individualContributors": [],
        "individualContributorsPresent": false,
        "relatedFiscalYearEnd": "2024-03-31",
        "relatedFiscalYearFinished": true,
        "relatedFiscalYearStart": "2023-04-01",
        "totalMembershipFees": {
            "from": 0,
            "to": 0
        }
    },
    "publicAllowances": {
        "publicAllowancesPresent": false,
        "relatedFiscalYearEnd": "2024-03-31",
        "relatedFiscalYearFinished": true,
        "relatedFiscalYearStart": "2023-04-01"
    },
    "registerEntryDetails": {
        "detailsPageUrl": "https://www.lobbyregister.bundestag.de/suche/R006335/36342",
        "fiscalYearUpdate": {
            "lastFiscalYearUpdate": "2024-06-25T14:05:03.000+02:00"
        },
        "pdfUrl": "https://www.lobbyregister.bundestag.de/media/64/64/311101/Lobbyregister-Detailansicht-R006335-2024-06-25_14-05-03.pdf",
        "validFromDate": "2024-06-25T14:05:03.000+02:00",
        "version": 2
    },
    "registerEntryId": 36342,
    "registerNumber": "R006335",
    "regulatoryProjects": {
        "regulatoryProjects": [],
        "regulatoryProjectsPresent": false
    },
    "statements": {}
}